Autolus Therapeutics (Autolus Therapeutics) Net Income Including Noncontrolling Interests : $-221.26 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Autolus Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was $-52.69 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was $-221.26 Mil.

Autolus Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Autolus Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics Net Income Including Noncontrolling Interests Chart

Autolus Therapeutics Annual Data

Trend

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income Including Noncontrolling Interests

Get a 7-Day Free Trial

-123.85

-142.09

-142.10

-148.84

-208.38

Autolus Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income Including Noncontrolling Interests	Get a 7-Day Free Trial															-39.81	-45.55	-45.85	-77.17	-52.69

Autolus Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-221.26 Mil.

Autolus Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Autolus Therapeutics (Autolus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » Net Income Including Noncontrolling Interests

Comparable Companies

Traded in Other Exchanges

6A3A:Germany

Address

191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Website

https://www.autolus.com

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.